Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 1
2001 1
2003 1
2005 4
2006 2
2007 4
2008 4
2009 5
2010 5
2011 4
2012 9
2013 7
2014 7
2015 6
2016 5
2017 6
2018 7
2019 4
2020 3
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24.0%; 52 symptomatic) in the donanemab group and 18 (2.1%; 0 symptomatic during study) in the placebo group and infusion-related reactions occurred in 74 participants (8 …
Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24.0%; 52 symptomatic) in the donanemab group …
The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis.
Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A; ISAAC Phase Three Study Group. Mallol J, et al. Allergol Immunopathol (Madr). 2013 Mar-Apr;41(2):73-85. doi: 10.1016/j.aller.2012.03.001. Epub 2012 Jul 6. Allergol Immunopathol (Madr). 2013. PMID: 22771150 Free article.
This ISAAC Phase Three synthesis provides summarised information on the main findings of the study, regional tables and figures related to the prevalence and severity of current symptoms of asthma, rhinoconjunctivitis and eczema in the main regions of …
This ISAAC Phase Three synthesis provides summarised information on the main findings of the study, regional tab …
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Langer CJ, et al. Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10. Lancet Oncol. 2016. PMID: 27745820 Free PMC article. Clinical Trial.
The incidence of grade 3 or worse treatment-related adverse events was similar between groups (23 [39%] of 59 patients in the pembrolizumab plus chemotherapy group and 16 [26%] of 62 in the chemotherapy alone group). The most common grade 3 or worse treatment-relate …
The incidence of grade 3 or worse treatment-related adverse events was similar between groups (23 [39%] of 59 patients in the pembrolizumab …
Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.
Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E, Ellwood P, García-Marcos L, Marks GB, Morales E, Mortimer K, Pérez-Fernández V, Robertson S, Silverwood RJ, Strachan DP, Pearce N; Global Asthma Network Phase I Study Group. Asher MI, et al. Lancet. 2021 Oct 30;398(10311):1569-1580. doi: 10.1016/S0140-6736(21)01450-1. Epub 2021 Oct 28. Lancet. 2021. PMID: 34755626 Free PMC article.
METHODS: This updated cross-sectional study used the same methods as the International study of Asthma and Allergies in Childhood (ISAAC) Phase III. Asthma symptoms were assessed from centres that completed GAN Phase I and ISAAC Phase …
METHODS: This updated cross-sectional study used the same methods as the International study of Asthma and Allergies in Childh …
Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H; ISAAC Phase Three Study Group. Asher MI, et al. Lancet. 2006 Aug 26;368(9537):733-43. doi: 10.1016/S0140-6736(06)69283-0. Lancet. 2006. PMID: 16935684
METHODS: For the ISAAC Phase Three study, between 2002 and 2003, we did a cross-sectional questionnaire survey of 193,404 children aged 6-7 years from 66 centres in 37 countries, and 304,679 children aged 13-14 years from 106 centres in 56 countries, c …
METHODS: For the ISAAC Phase Three study, between 2002 and 2003, we did a cross-sectional questionnaire survey o …
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. Aghajanian C, et al. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. Gynecol Oncol. 2018. PMID: 29804638 Free PMC article. Clinical Trial.
OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial, patients with c …
OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tole …
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Ascierto PA, et al. Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19. Lancet Oncol. 2020. PMID: 32961119 Clinical Trial.
Late-emergent grade 3-4 treatment-related adverse events were reported in three (1%) of 452 and seven (2%) of 453 patients. The most common late-emergent treatment-related grade 3 or 4 adverse events reported were diarrhoea, diabetic ketoacidosis, and pneumonitis (one pati …
Late-emergent grade 3-4 treatment-related adverse events were reported in three (1%) of 452 and seven (2%) of 453 patients. The most …
Comparison of individual-level and population-level risk factors for rhinoconjunctivitis, asthma, and eczema in the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three.
Rutter CE, Silverwood RJ, Asher MI, Ellwood P, Pearce N, Garcia-Marcos L, Strachan DP; ISAAC Phase Three Study Group. Rutter CE, et al. World Allergy Organ J. 2020 Jul 2;13(6):100123. doi: 10.1016/j.waojou.2020.100123. eCollection 2020 Jun. World Allergy Organ J. 2020. PMID: 32642022 Free PMC article.
OBJECTIVES: To assess individual-level and school-level risk factors for symptoms of rhinoconjunctivitis and compare them to corresponding associations with symptoms of asthma and eczema in Phase Three of the International Study of Asthma and Allergies in Chi …
OBJECTIVES: To assess individual-level and school-level risk factors for symptoms of rhinoconjunctivitis and compare them to corresponding a …
Are environmental risk factors for current wheeze in the International Study of Asthma and Allergies in Childhood (ISAAC) phase three due to reverse causation?
Silverwood RJ, Rutter CE, Mitchell EA, Asher MI, Garcia-Marcos L, Strachan DP, Pearce N; ISAAC Phase Three Study Group. Silverwood RJ, et al. Clin Exp Allergy. 2019 Apr;49(4):430-441. doi: 10.1111/cea.13325. Epub 2019 Jan 23. Clin Exp Allergy. 2019. PMID: 30508327 Free PMC article.
BACKGROUND: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) measured the global prevalence of symptoms of asthma in children. ...
BACKGROUND: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) measured the glo …
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.
García-Marcos L, Asher MI, Pearce N, Ellwood E, Bissell K, Chiang CY, El Sony A, Ellwood P, Marks GB, Mortimer K, Martínez-Torres AE, Morales E, Perez-Fernandez V, Robertson S, Rutter CE, Silverwood RJ, Strachan DP; Global Asthma Network Phase I Study Group. García-Marcos L, et al. Eur Respir J. 2022 Sep 15;60(3):2102866. doi: 10.1183/13993003.02866-2021. Print 2022 Sep. Eur Respir J. 2022. PMID: 35144987 Free PMC article. Clinical Trial.
AIMS: There have been no worldwide standardised surveys of prevalence and severity of asthma, rhinoconjunctivitis and eczema in school children for 15 years. The present study aims to provide this information. METHODS: Following the exact International Study of Asth …
AIMS: There have been no worldwide standardised surveys of prevalence and severity of asthma, rhinoconjunctivitis and eczema in school child …
84 results